Everything we've seen

1. ?Nov 13, 7:30 PMdecisionconsidered

   Agent 4 — Dip Buyer (Frozen) — decide: skip

   XRAY (Dentsply Sirona) is down 14.4% from its 30-day high with no news headlines in the window to explain the move, suggesting the decline may be technically or sentiment-driven rather than fundamentally catalyzed. However, the SEC filings (10-Q and 8-Ks) carry no extractable metrics, leaving financial health unverifiable from this data alone — XRAY has had a troubled recent history of guidance cuts and restructuring that warrants conservatism. The macro backdrop shows inflation expectations (T10YIE at 2.2, 1.7σ below trend) that are benign for equities broadly, but XRAY is in a cyclical dental equipment sector that has faced secular demand headwinds, limiting mean-reversion confidence.

2. !Nov 13, 7:30 PMsignalseverity 0.15

   Agent 4 — Dip Buyer (Frozen) — dip_skipped

   XRAY (Dentsply Sirona) is down 14.4% from its 30-day high with no news headlines in the window to explain the move, suggesting the decline may be technically or sentiment-driven rather than fundamentally catalyzed. However, the SEC filings (10-Q and 8-Ks) carry no extractable metrics, leaving financial health unverifiable from this data alone — XRAY has had a troubled recent history of guidance cuts and restructuring that warrants conservatism. The macro backdrop shows inflation expectations (T10YIE at 2.2, 1.7σ below trend) that are benign for equities broadly, but XRAY is in a cyclical dental equipment sector that has faced secular demand headwinds, limiting mean-reversion confidence.

3. ?Nov 13, 3:20 PMdecisionconsidered

   Agent 5 — Dip Buyer (Evolving) — decide: skip

   XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

4. !Nov 13, 3:20 PMsignalseverity 0.14

   Agent 5 — Dip Buyer (Evolving) — dip_skipped

   XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

5. ?Nov 13, 3:20 PMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

6. !Nov 13, 3:20 PMsignalseverity 0.14

   Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

   XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

7. ?Nov 13, 2:21 PMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

8. !Nov 13, 2:21 PMsignalseverity 0.14

   Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

   XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

9. ?Nov 13, 2:21 PMdecisionconsidered

   Agent 5 — Dip Buyer (Evolving) — decide: skip

   XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

10. !Nov 13, 2:21 PMsignalseverity 0.14

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

11. ?Nov 13, 1:23 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

12. !Nov 13, 1:23 PMsignalseverity 0.14

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

13. ?Nov 13, 1:23 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

14. !Nov 13, 1:23 PMsignalseverity 0.14

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

15. ?Nov 13, 11:36 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

16. !Nov 13, 11:36 AMsignalseverity 0.14

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

17. ?Nov 12, 7:30 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    XRAY (Dentsply Sirona) is down 14.4% from its 30-day high with no news headlines in the window to explain the move, suggesting the decline may be technically or sentiment-driven rather than fundamentally catalyzed. However, the SEC filings (10-Q and 8-Ks) carry no extractable metrics, leaving financial health unverifiable from this data alone — XRAY has had a troubled recent history of guidance cuts and restructuring that warrants conservatism. The macro backdrop shows inflation expectations (T10YIE at 2.2, 1.7σ below trend) that are benign for equities broadly, but XRAY is in a cyclical dental equipment sector that has faced secular demand headwinds, limiting mean-reversion confidence.

18. !Nov 12, 7:30 PMsignalseverity 0.14

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    XRAY (Dentsply Sirona) is down 14.4% from its 30-day high with no news headlines in the window to explain the move, suggesting the decline may be technically or sentiment-driven rather than fundamentally catalyzed. However, the SEC filings (10-Q and 8-Ks) carry no extractable metrics, leaving financial health unverifiable from this data alone — XRAY has had a troubled recent history of guidance cuts and restructuring that warrants conservatism. The macro backdrop shows inflation expectations (T10YIE at 2.2, 1.7σ below trend) that are benign for equities broadly, but XRAY is in a cyclical dental equipment sector that has faced secular demand headwinds, limiting mean-reversion confidence.

19. ?Nov 12, 3:10 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    XRAY is down 4.46% with only 35 minutes remaining until the forced close. The move is meaningful in magnitude, suggesting real institutional flow, but the time constraint is severe — with 35 minutes left, there is limited runway for continuation to reach the +3% profit target from current levels. No headline catalyst is present to explain the drop or sustain momentum. The macro context (T10YIE at 1.7σ below trend, favorable for long-duration sensitive sectors) is mildly contrary to continued selling pressure in a beaten-down equity like XRAY. With late-session positioning, there is elevated risk of short covering or mean reversion into the close as traders flatten. The combination of very limited time remaining, no news catalyst, and a macro backdrop that leans against further selling pushes this below the 0.5 threshold — the reversal/fade risk into the close slightly outweighs continuation probability.

20. !Nov 12, 3:10 PMsignalseverity -0.04

    Agent 7 — Day Trader — day_trade_skipped

    XRAY is down 4.46% with only 35 minutes remaining until the forced close. The move is meaningful in magnitude, suggesting real institutional flow, but the time constraint is severe — with 35 minutes left, there is limited runway for continuation to reach the +3% profit target from current levels. No headline catalyst is present to explain the drop or sustain momentum. The macro context (T10YIE at 1.7σ below trend, favorable for long-duration sensitive sectors) is mildly contrary to continued selling pressure in a beaten-down equity like XRAY. With late-session positioning, there is elevated risk of short covering or mean reversion into the close as traders flatten. The combination of very limited time remaining, no news catalyst, and a macro backdrop that leans against further selling pushes this below the 0.5 threshold — the reversal/fade risk into the close slightly outweighs continuation probability.

21. ?Nov 12, 2:36 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

22. !Nov 12, 2:36 PMsignalseverity 0.14

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

23. ?Nov 12, 1:45 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    XRAY is down 3.59% with no headline catalyst identified, suggesting this is flow/technical driven rather than news-driven. The macro context (T10YIE at 1.7σ below 24-month trend, indicating lower inflation expectations) is modestly supportive of risk assets in general, which could create a mild headwind against further downside continuation. With 120 minutes remaining there is ample time for continuation or reversal. The move is meaningful in size (near the upper bound of a typical intraday range) and represents real conviction selling, but without a news catalyst or clear sector tailwind for the down move, and with a macro backdrop that is not overtly bearish, momentum continuation is plausible but not compelling. No reversal signals are explicitly present either. This resolves as a borderline case — momentum is modestly favored to continue given the size of the move and time remaining, but macro context slightly tempers conviction. Assigning 0.50 as a floor given the system's asymmetric risk/reward and absence of a clear fade signal.

24. !Nov 12, 1:45 PMsignalseverity -0.04

    Agent 7 — Day Trader — day_trade_skipped

    XRAY is down 3.59% with no headline catalyst identified, suggesting this is flow/technical driven rather than news-driven. The macro context (T10YIE at 1.7σ below 24-month trend, indicating lower inflation expectations) is modestly supportive of risk assets in general, which could create a mild headwind against further downside continuation. With 120 minutes remaining there is ample time for continuation or reversal. The move is meaningful in size (near the upper bound of a typical intraday range) and represents real conviction selling, but without a news catalyst or clear sector tailwind for the down move, and with a macro backdrop that is not overtly bearish, momentum continuation is plausible but not compelling. No reversal signals are explicitly present either. This resolves as a borderline case — momentum is modestly favored to continue given the size of the move and time remaining, but macro context slightly tempers conviction. Assigning 0.50 as a floor given the system's asymmetric risk/reward and absence of a clear fade signal.

25. ?Nov 12, 12:40 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    XRAY is down ~3.89% intraday with no attributable headline, suggesting this is likely a technical or flow-driven sell-off. A move of this magnitude represents real conviction from sellers. The macro context (T10YIE at 1.7σ below trend, i.e. lower real rate expectations) is modestly supportive of long-duration sensitive sectors and would not typically provide a tailwind for a dental equipment/supply name like XRAY — it's a slight headwind to any reversal thesis. With 185 minutes remaining, there is ample time for continuation into the close. No reversal signals are evident from the data provided, and absence of news does not negate the momentum. The setup is ordinary momentum with no strong countervailing factor, so a modest continuation probability just above the threshold is appropriate. The bounded risk profile (1.5% stop, 3% target) makes this a marginal but actionable short.

26. !Nov 12, 12:40 PMsignalseverity -0.04

    Agent 7 — Day Trader — day_trade_skipped

    XRAY is down ~3.89% intraday with no attributable headline, suggesting this is likely a technical or flow-driven sell-off. A move of this magnitude represents real conviction from sellers. The macro context (T10YIE at 1.7σ below trend, i.e. lower real rate expectations) is modestly supportive of long-duration sensitive sectors and would not typically provide a tailwind for a dental equipment/supply name like XRAY — it's a slight headwind to any reversal thesis. With 185 minutes remaining, there is ample time for continuation into the close. No reversal signals are evident from the data provided, and absence of news does not negate the momentum. The setup is ordinary momentum with no strong countervailing factor, so a modest continuation probability just above the threshold is appropriate. The bounded risk profile (1.5% stop, 3% target) makes this a marginal but actionable short.

27. ?Nov 12, 11:31 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    XRAY is down ~3.94% with 255 minutes remaining — substantial time for continuation. No headline catalyst is present, but absence of news doesn't disqualify the move; someone with size initiated this selloff. The macro context shows 10-year inflation expectations (T10YIE) printing 1.7σ below trend at 2.2, which is modestly supportive of long-duration assets and would typically provide a mild headwind to a falling equity — however, XRAY is a dental products company (consumer/healthcare staples-adjacent) and not particularly long-duration sensitive, so this macro read is largely neutral here. With no reversal signals noted, no news to fade the move, and ample time remaining, the base case is mild continuation of the downward momentum. Probability stays modest at 0.52 given the lack of confirmatory volume data or clear sector-level pressure — this is an ordinary momentum read with no strong reason to expect a fade.

28. !Nov 12, 11:31 AMsignalseverity -0.04

    Agent 7 — Day Trader — day_trade_skipped

    XRAY is down ~3.94% with 255 minutes remaining — substantial time for continuation. No headline catalyst is present, but absence of news doesn't disqualify the move; someone with size initiated this selloff. The macro context shows 10-year inflation expectations (T10YIE) printing 1.7σ below trend at 2.2, which is modestly supportive of long-duration assets and would typically provide a mild headwind to a falling equity — however, XRAY is a dental products company (consumer/healthcare staples-adjacent) and not particularly long-duration sensitive, so this macro read is largely neutral here. With no reversal signals noted, no news to fade the move, and ample time remaining, the base case is mild continuation of the downward momentum. Probability stays modest at 0.52 given the lack of confirmatory volume data or clear sector-level pressure — this is an ordinary momentum read with no strong reason to expect a fade.

29. ?Nov 12, 10:20 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

30. !Nov 12, 10:20 AMsignalseverity 0.13

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

31. ?Nov 12, 10:20 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

32. !Nov 12, 10:20 AMsignalseverity 0.13

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

33. ?Nov 12, 10:11 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    XRAY is down 3.53% with no headline catalyst visible, suggesting this is flow-driven selling with some conviction behind it. The move is at the lower bound of the 'meaningful' range (2-5%), so it carries real signal but isn't a blowout. No news to anchor a reversal narrative. Macro context shows 10Y inflation expectations (T10YIE) printing notably below trend at 2.2 (1.7σ low), which is modestly supportive of risk assets in general but XRAY is a dental/med-tech name not particularly long-duration sensitive — this macro factor is largely neutral here. With 335 minutes remaining there is ample time for continuation but also for mean reversion. No reversal pattern identified; the absence of a bounce so far suggests sellers remain in control mid-session. No strong volume data to flag, so no thin-volume caution applied. Overall: modest continuation bias — selling pressure hasn't been countered by any identifiable catalyst, and time is not a limiting factor. Probability sits just above the threshold reflecting ordinary momentum with no strong reversal signal.

34. !Nov 12, 10:11 AMsignalseverity -0.04

    Agent 7 — Day Trader — day_trade_skipped

    XRAY is down 3.53% with no headline catalyst visible, suggesting this is flow-driven selling with some conviction behind it. The move is at the lower bound of the 'meaningful' range (2-5%), so it carries real signal but isn't a blowout. No news to anchor a reversal narrative. Macro context shows 10Y inflation expectations (T10YIE) printing notably below trend at 2.2 (1.7σ low), which is modestly supportive of risk assets in general but XRAY is a dental/med-tech name not particularly long-duration sensitive — this macro factor is largely neutral here. With 335 minutes remaining there is ample time for continuation but also for mean reversion. No reversal pattern identified; the absence of a bounce so far suggests sellers remain in control mid-session. No strong volume data to flag, so no thin-volume caution applied. Overall: modest continuation bias — selling pressure hasn't been countered by any identifiable catalyst, and time is not a limiting factor. Probability sits just above the threshold reflecting ordinary momentum with no strong reversal signal.

35. ?Nov 11, 1:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

36. !Nov 11, 1:20 PMsignalseverity 0.11

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

37. ?Nov 11, 1:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

38. !Nov 11, 1:20 PMsignalseverity 0.11

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

39. ?Nov 11, 12:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

40. !Nov 11, 12:20 PMsignalseverity 0.12

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

41. ?Nov 11, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

42. !Nov 11, 12:20 PMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

43. ?Nov 11, 10:21 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

44. ?Nov 11, 10:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

45. !Nov 11, 10:21 AMsignalseverity 0.12

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

46. !Nov 11, 10:21 AMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

47. ?Nov 11, 9:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

48. !Nov 11, 9:21 AMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

49. ?Nov 11, 9:21 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

50. !Nov 11, 9:21 AMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

51. ?Nov 10, 7:31 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    XRAY (Dentsply Sirona) is down 12.4% from its 30-day high with no news headlines in the window to explain the drop, suggesting the move may be technically or sentiment-driven rather than fundamentally justified. However, the SEC filings (10-Q and 8-K filed 2026-11-05) carry no reported metrics, making it impossible to assess recent financial performance — this uncertainty is a meaningful handicap for conviction. The macro context (elevated mortgage rates at 7.18%, 1.9σ above trend) is not directly relevant to XRAY's dental equipment/consumables business, offering neither a tailwind nor a headwind specific to the company.

52. !Nov 10, 7:31 PMsignalseverity 0.10

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    XRAY (Dentsply Sirona) is down 12.4% from its 30-day high with no news headlines in the window to explain the drop, suggesting the move may be technically or sentiment-driven rather than fundamentally justified. However, the SEC filings (10-Q and 8-K filed 2026-11-05) carry no reported metrics, making it impossible to assess recent financial performance — this uncertainty is a meaningful handicap for conviction. The macro context (elevated mortgage rates at 7.18%, 1.9σ above trend) is not directly relevant to XRAY's dental equipment/consumables business, offering neither a tailwind nor a headwind specific to the company.

53. ?Nov 10, 3:37 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    With only 9 minutes remaining until the forced close, there is simply insufficient time for meaningful continuation even if momentum is intact. The 1.83% move is real but sits at the lower end of the 'meaningful' threshold. No catalyzing headlines exist to explain or sustain the flow. The macro context (elevated DFF, banks/money-market reactive sectors) is not particularly supportive for a dental equipment name like XRAY. At 9 minutes to cutoff, the dominant dynamic becomes EOD position flattening and profit-taking by intraday longs who entered earlier in the session, which creates natural fade pressure. The asymmetric time risk — almost no runway to reach the +3% target from current levels (~+1.17% needed) in 9 minutes while stop risk remains — further argues against entering. Probability set below 0.5 primarily on time-remaining constraint.

54. !Nov 10, 3:37 PMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    With only 9 minutes remaining until the forced close, there is simply insufficient time for meaningful continuation even if momentum is intact. The 1.83% move is real but sits at the lower end of the 'meaningful' threshold. No catalyzing headlines exist to explain or sustain the flow. The macro context (elevated DFF, banks/money-market reactive sectors) is not particularly supportive for a dental equipment name like XRAY. At 9 minutes to cutoff, the dominant dynamic becomes EOD position flattening and profit-taking by intraday longs who entered earlier in the session, which creates natural fade pressure. The asymmetric time risk — almost no runway to reach the +3% target from current levels (~+1.17% needed) in 9 minutes while stop risk remains — further argues against entering. Probability set below 0.5 primarily on time-remaining constraint.

55. ?Nov 10, 2:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

56. !Nov 10, 2:20 PMsignalseverity 0.11

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

57. ?Nov 10, 2:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

58. !Nov 10, 2:20 PMsignalseverity 0.11

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

59. ?Nov 10, 1:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

60. !Nov 10, 1:20 PMsignalseverity 0.11

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

61. ?Nov 10, 1:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

62. ?Nov 10, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

63. ?Nov 10, 12:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

64. ?Nov 10, 11:20 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

65. ?Nov 10, 11:20 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

66. ?Nov 10, 9:50 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    XRAY is down 2.36% with no attributable headlines, suggesting this is likely flow-driven or sector/sympathy selling. The macro context (elevated DFF at 2.0σ above trend) is modestly negative for risk assets broadly but not directly sector-relevant to dental/medtech. With 355 minutes remaining there is ample time for continuation or reversal. The move is at the lower boundary of the 2-5% 'meaningful' range, so conviction is moderate but not overwhelming. No reversal signals are evident from the data provided, and absence of news does not disqualify the momentum thesis. No strong catalyst to expect a fade, but equally no clear continuation pressure beyond the initial move itself. Assigning baseline continuation probability at 0.5 — sufficient to trigger a position given bounded downside risk and the system's stop/target structure, but not high-conviction.

67. ?Nov 9, 12:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

68. ?Nov 9, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

69. ?Nov 9, 11:20 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

70. ?Nov 9, 11:20 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

71. ?Nov 9, 10:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

72. ?Nov 9, 10:21 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

73. ?Nov 9, 9:20 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

74. ?Nov 9, 9:20 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

75. ?Nov 9, 6:01 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

76. ?Nov 9, 6:01 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

77. ?Nov 6, 7:32 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    XRAY (Dentsply Sirona) is down 12.4% from its 30-day high with no news headlines in the window to explain the drop, suggesting the move may be technically or sentiment-driven rather than fundamentally justified. However, the SEC filings (10-Q and 8-K filed 2026-11-05) carry no reported metrics, making it impossible to assess recent financial performance — this uncertainty is a meaningful handicap for conviction. The macro context (elevated mortgage rates at 7.18%, 1.9σ above trend) is not directly relevant to XRAY's dental equipment/consumables business, offering neither a tailwind nor a headwind specific to the company.

78. ?Nov 6, 3:10 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    XRAY is down 6.59% with only 35 minutes remaining until the forced close. The move is significant and represents real institutional flow, but several factors argue against continuation: (1) With only 35 minutes left, there is very little time for the trade to reach the +3% profit target from current levels — the remaining runway is too short for a fresh entry to work cleanly. (2) A -6.59% move of this magnitude in a single session, absent any identifiable catalyst or news, often sees mean-reversion buying pressure emerge in the final hour as opportunistic buyers step in and shorts cover into the close. (3) The macro context (elevated mortgage rates) is not directly relevant to XRAY (a dental products company), providing no incremental tailwind for the downside. (4) With no news to anchor the selloff, the move may have been driven by a single large seller who could be exhausted. The setup does not meet the 0.5 threshold primarily due to the extreme time constraint making the risk/reward unfavorable for a continuation trade.

79. ?Nov 6, 1:21 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    XRAY is down 12.6% from its 30-day high with no clear fundamental catalyst visible — no news headlines, no meaningful metrics in recent SEC filings, and no insider activity to explain the drop or signal conviction either way. The Health Care sector (XLV) is a relative outperformer (+13.35pts vs SPY over 30 days), meaning XRAY's dip is idiosyncratic rather than sector-driven, which introduces stock-specific risk. The macro environment is broadly constructive today (VIX at 39th percentile, QQQ +2.15%, SPY +1.05%), providing a mild tailwind, but the absence of any confirmation signals (no insider buys, no unusual call flow, no analyst commentary) limits upside conviction.

80. ?Nov 6, 1:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    XRAY (Dentsply Sirona) is down 12.6% from its 30-day high with no hard veto triggers: no imminent earnings, no visible fundamental deterioration in the 10-Q/8-K filings (metrics empty, no red-flag language surfaced), and no going-concern or guidance-cut disclosures apparent. The sector (Health Care/XLV) is a relative strength leader — ranked 3rd of 11 and outperforming SPY by +13.35pts over 30 days — which makes this a single-stock idiosyncratic drop rather than a sector-wide dip, reducing mean-reversion confidence. Signal scoring: +1 for no earnings within 30 days, +1 for no fundamental impairment; -1 for single-stock drop while sector outperforms (idiosyncratic risk), -1 for high 10Y yield (4.90%, above 4.5% headwind threshold for a dental equipment/value name under margin pressure), leaving a net score of 0. The drop magnitude is only 12.6% (below the 15% threshold for a bonus positive signal), no insider activity, no options flow data, and macro is mixed. With a net score of 0 and no strong cluster buy or unusual call flow to override, the evidence is marginal and does not reach the threshold for a confident buy.

81. ▣Sep 14, 8:00 PMjournalstop

    Agent 5 — Dip Buyer (Evolving) closed long 124 @ $10.04 (-$112.84)

    intraday stop sweep

82. ❖Sep 11, 1:15 PMnewsvia finnhub

    3 Russell 2000 Stocks We Steer Clear Of

    The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.

83. ❖Sep 8, 12:13 PMnewsvia finnhub

    XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure

    XRAY beat Q2 earnings and revenue estimates, held 2026 guidance and improved cash flow, but falling sales and margin pressure cloud the recovery.

84. ❖Sep 4, 12:13 PMnewsvia finnhub

    DENTSPLY SIRONA (XRAY) Returns To Profit As Investors Weigh Its Valuation

    DENTSPLY SIRONA (XRAY) shares are in focus after the company reported second quarter 2026 results that returned the business to profitability while net sales declined 4.1% year over year. The latest results and upcoming appearance at the Baird 2026 Global Healthcare Conference come after a mixed share price pattern for DENTSPLY SIRONA, with a 7 day share price return of 3.53% but a 30 day share price return that declined 19.90%. Recent momentum has been choppy, as a 90 day share price return...

85. ❖Sep 4, 10:13 AMnewsvia finnhub

    Dentsply Sirona (XRAY) Stock May Still Trade At A Discount

    DENTSPLY SIRONA stock has had a difficult run over the past few years, yet on broad valuation checks it now screens as one of the cheaper options in its peer group. The share price history and the current multiples are sending very different signals about what the market expects from the business. Over the past 5 years, DENTSPLY SIRONA shareholders have seen the stock fall about 79.6%, which points to a long period of weak sentiment that still weighs on expectations today. The valuation...

86. ❖Sep 4, 3:20 AMnewsvia finnhub

    Does XRAY’s Profit Recovery and Reaffirmed 2026 Outlook Shift the Dentsply Sirona Thesis?

    Dentsply Sirona recently reported second-quarter 2026 results showing a 4.1% year-over-year net sales decline but a return to net income, with higher margins and stronger cash generation, and also confirmed it will present at the Baird 2026 Global Healthcare Conference on September 15, 2026. The combination of improved profitability and cash flow, despite weaker revenue and a history of pressure on returns, led management to reiterate full-year 2026 guidance, highlighting a sharper focus on...

87. ❖Sep 3, 4:15 PMnewsvia finnhub

    Dentsply Sirona to Participate in the Baird 2026 Global Healthcare Conference

    CHARLOTTE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Baird 2026 Global Healthcare Conference. Management is scheduled to present on Tuesday, September 15, 2026, at 11:25 a.m. ET. Investors and other interested parties will be able to access a live audio webcast and an audio webcast replay by visiting the Investors section of the Dentsply Sirona website at https://inves

88. ❖Sep 3, 6:38 AMnewsvia finnhub

    Dentsply Sirona (XRAY) Swings Back To Profit While Sales Keep Sliding

    On August 6, Dentsply Sirona (NASDAQ:XRAY) reported second-quarter 2026 results that pulled the stock in two directions at once. Net sales fell 4.1% year over year to $898 million, yet the company swung from a $45 million net loss a year earlier to $37 million in net income, with diluted earnings per share of $0.18 […]

89. ❖Sep 3, 4:31 AMnewsvia finnhub

    1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds

    Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 25.1% over the past six months, topping the S&P 500 by 13.1 percentage points.

90. ❖Aug 24, 6:17 AMnewsvia finnhub

    Barclays Maintains Underweight on Dentsply Sirona, Raises Price Target to $11

    Barclays analyst Glen Santangelo maintains Dentsply Sirona (NASDAQ:XRAY) with a Underweight and raises the price target from $9 to $11.

91. ▢Aug 23, 8:00 PMjournal

    Agent 5 — Dip Buyer (Evolving) opened long 124 @ $10.95

92. ❖Aug 11, 12:13 AMnewsvia finnhub

    Why Dentsply Sirona (XRAY) Stock Is Trading Lower Today

    Shares of dental products company Dentsply Sirona (NASDAQ:XRAY) fell 6.8% in the afternoon session after the company reported second-quarter 2026 earnings, which featured a beat on profit estimates, was overshadowed by a weak full-year revenue forecast.

93. ❖Aug 7, 5:04 PMnewsvia finnhub

    DENTSPLY SIRONA Q2 Earnings Call Highlights

    DENTSPLY SIRONA (NASDAQ:XRAY) reported second-quarter 2026 revenue of $898 million, down 4.1% on a reported basis and 6.3% on a constant-currency basis, as the dental products company continued its turnaround plan amid lower volumes in several businesses and distributor inventory reductions in Europ

94. ❖Aug 7, 4:13 PMnewsvia finnhub

    1% Undervalued? DENTSPLY SIRONA (XRAY) As Earnings Test Its Recovery Story

    Earnings trigger and recent business updates DENTSPLY SIRONA (XRAY) is in focus after reporting second quarter 2026 earnings on 6 August, alongside reaffirmed full year net sales guidance and an update on long running share repurchases. The company reported quarterly sales of US$898 million compared with US$936 million a year earlier. Net income for the quarter was US$37 million compared with a net loss of US$45 million in the prior year period, with basic and diluted earnings per share from...

95. ❖Aug 7, 2:35 PMnewsvia finnhub

    XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales

    DENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.

96. ❖Aug 7, 9:30 AMnewsvia finnhub

    Here's What Key Metrics Tell Us About Dentsply (XRAY) Q2 Earnings

    The headline numbers for Dentsply (XRAY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

97. ❖Aug 6, 7:02 PMnewsvia finnhub

    DENTSPLY SIRONA Inc. 2026 Q2 - Results - Earnings Call Presentation

    2026-08-06. The following slide deck was published by DENTSPLY SIRONA Inc.

98. ❖Aug 6, 5:40 PMnewsvia finnhub

    Dentsply International (XRAY) Beats Q2 Earnings and Revenue Estimates

    Dentsply (XRAY) delivered earnings and revenue surprises of +44.44% and +1.60%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

99. ❖Aug 6, 4:54 PMnewsvia finnhub

    DENTSPLY SIRONA Inc. (XRAY) Q2 2026 Earnings Call Transcript

    DENTSPLY SIRONA Inc. (XRAY) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsWade Moody - Senior Manager of Investor RelationsDaniel...

100. ❖Aug 6, 4:37 PMnewsvia finnhub

     Dentsply Sirona (NASDAQ:XRAY) Beats Q2 CY2026 Sales Expectations

     Dental products company Dentsply Sirona (NASDAQ:XRAY) reported Q2 CY2026 results topping the market’s revenue expectations, but sales fell by 4.1% year on year to $898 million. On the other hand, the company’s full-year revenue guidance of $3.55 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $0.52 per share was 50.1% above analysts’ consensus estimates.

101. ❖Aug 6, 4:01 PMnewsvia finnhub

     Dentsply Sirona Reports Second Quarter 2026 Results

     News Summary Reported net sales of $898 millionDelivered GAAP gross margin of 54.9%, GAAP diluted earnings per share of $0.18Achieved adjusted gross margin of 56.4%, adjusted EBITDA margin of 21.3%, adjusted EPS of $0.52Announced expanded partnership with Medline Sinclair, broadening access to Connected Technology Solutions portfolio across CanadaRepurchased 1.3 million shares of common stock during the quarterReiterates 2026 outlook for net sales and adjusted EPS CHARLOTTE, N.C., Aug. 06, 2026

102. ❖Aug 6, 12:08 PMnewsvia finnhub

     Dentsply Sirona Affirms FY2026 Adj EPS Guidance of $1.40-$1.50 vs $1.42 Est; Affirms FY2026 Sales Guidance of $3.500B-$3.600B vs $3.582B Est

     Dentsply Sirona (NASDAQ:XRAY) affirms FY2026 Adj EPS guidance from $1.40-$1.50 to $1.40-$1.50 vs $1.42 analyst estimate. Affirms FY2026 sales outlook from $3.500 billion-$3.600 billion to $3.500 billion-$3.600 billion

103. ❖Aug 6, 12:04 PMnewsvia finnhub

     Dentsply Sirona Q2 Adj. EPS $0.52 Beats $0.35 Estimate, Sales $898.000M Beat $889.810M Estimate

     Dentsply Sirona (NASDAQ:XRAY) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.35 by 48.57 percent. This is unchanged from the same period last year. The company reported

104. ❖Aug 4, 12:22 PMnewsvia finnhub

     DENTSPLY SIRONA to Post Q2 Earnings: What's in Store for the Stock?

     XRAY's Q2 results are likely to reflect transformation investments, dealer inventory cuts and weak implants, while Wellspect growth offers support.

105. ❖Aug 3, 11:07 AMnewsvia finnhub

     Can Dentsply Sirona (XRAY) Turn Its Business Around?

     Ariel Investments, an investment management company, released its “Ariel Focus Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund returned 2.14% in the second quarter of 2026, underperforming the Russell 1000 Value and S&P 500, which gained 13.87% and 15.20%, respectively. The fund benefited from gains in several […]

106. ▣Jul 30, 8:00 PMjournalexpired_settlement

     options_momentum closed long 700 @ $2.37 (+$1,260.13)

     SETTLED 2026-09-17 (mig 257): contract expired 2026-07-31 while the agent was disabled; settled at intrinsic 2.3700 from underlying close 13.37 (Massive, unadjusted). Was carried at stale 7/2 mark 0.9210.

107. ❖Jul 29, 9:17 AMnewsvia finnhub

     Piper Sandler Maintains Neutral on Dentsply Sirona, Raises Price Target to $14

     Piper Sandler analyst Jason Bednar maintains Dentsply Sirona (NASDAQ:XRAY) with a Neutral and raises the price target from $13 to $14.

108. ❖Jul 28, 8:30 AMnewsvia finnhub

     Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship

     The expansion marks Dentsply Sirona's sixth dealer network enhancement announced in 2026, further advancing its strategy to broaden access to digital dentistry solutions through trusted distribution partnersCHARLOTTE, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- Dentsply Sirona, the world's largest diversified manufacturer of professional dental products and technologies, today announced an expansion of its long-standing relationship with Medline Sinclair, one of Canada's leading full-service dental

109. ❖Jul 24, 2:57 PMnewsvia finnhub

     3 Reasons to Sell XRAY and 1 Stock to Buy Instead

     Dentsply Sirona has been treading water for the past six months, recording a small loss of 0.5% while holding steady at $12.66. The stock also fell short of the S&P 500’s 7.9% gain during that period.

110. ❖Jul 21, 4:15 PMnewsvia finnhub

     Dentsply Sirona to Host Second Quarter Conference Call on August 6th

     CHARLOTTE, N.C., July 21, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, August 6, 2026, at 4:30 p.m. ET to review its second quarter 2026 financial results. Financial earnings materials will be made available on the Investors section of the Company’s website at https://investor.dentsplysirona.com prior to the call. Conference Call / Webcast Info

111. ❖Jul 19, 9:52 PMnewsvia finnhub

     Ariel Focus Fund Q2 2026 Portfolio Activity

     Boutique asset manager, Affiliated Managers Group, Inc. advanced during the quarter, with strong momentum in its alternatives platform. Read more here.

112. ❖Jul 13, 9:26 AMnewsvia finnhub

     Q2 2026 Earnings Preview: Navigating High Expectations, Tariff Rebates, And War Uncertainties

     Wall Street analysts expect Q2 S&P 500 profit growth of 23.6%, which could mark the 7th consecutive quarter of double-digit earnings growth.

113. ❖Jul 10, 7:03 AMnewsvia finnhub

     Solving A Lackluster Growth Outlook Should Be Solventum's Next Priority

     Solventum Corporation trades at a discount with 20%+ upside from restructuring and portfolio moves despite slow growth. Click for this SOLV update.

114. ❖Jul 9, 6:25 AMnewsvia finnhub

     BMO Capital Initiates Coverage On Dentsply Sirona with Market Perform Rating, Announces Price Target of $12

     BMO Capital initiates coverage on Dentsply Sirona (NASDAQ:XRAY) with a Market Perform rating and announces Price Target of $12.

115. ❖Jul 7, 8:35 AMnewsvia finnhub

     Dentsply Sirona: The Recovery Story Needs More Than A Stock Rebound

     DENTSPLY SIRONA recovery watch: Q1 sales -6.7%, margin 14.7%, FCF -$12M. Click for more on XRAY stock.

116. ❖Jul 7, 5:42 AMnewsvia finnhub

     DENTSPLY SIRONA Inc. (XRAY)’s Shares Are Flat Since Cramer Commented On Them

     We recently published Jim Cramer’s Biggest Losers: 10 Stocks That Just Didn’t Work Out. DENTSPLY SIRONA Inc. (NASDAQ:XRAY) is one of the stocks discussed by Jim Cramer. DENTSPLY SIRONA Inc. (NASDAQ:XRAY) is a dental products manufacturer. Its shares are down by 26.9% over the past year and are up by 3.4% year-to-date. Soon after Cramer […]

117. ❖Jul 1, 5:00 PMnewsvia finnhub

     PDS Health Surpasses Five Million CEREC Chairside Restorations with Dentsply Sirona, Marking a Major Milestone in Scaled Digital Dentistry

     This milestone reflects PDS Health’s continued investment in digital technologies that help practices operate more efficiently, expand access to same-day restorative care and deliver a more consistent experience for patients.CHARLOTTE, N.C., July 01, 2026 (GLOBE NEWSWIRE) -- PDS Health® and Dentsply Sirona today announced that PDS Health practices have surpassed five million CEREC chairside restorations, a milestone that underscores the scale, consistency and long-term integration of digital res

118. ▢Jun 30, 8:00 PMjournal

     options_momentum opened long 700 @ $0.57

119. ▣Jun 29, 8:00 PMjournalstop

     options_momentum closed long 800 @ $0.35 (-$118.90)

     Stop: premium $0.35 ≤ trailing floor $0.44 (peak $0.59 × 0.75)

120. ▢Jun 24, 8:00 PMjournal

     options_momentum opened long 800 @ $0.50

121. ❖Jun 24, 8:08 AMnewsvia finnhub

     Dental Equipment & Technology Stocks Q1 In Review: Dentsply Sirona (NASDAQ:XRAY) Vs Peers

     Wrapping up Q1 earnings, we look at the numbers and key takeaways for the dental equipment & technology stocks, including Dentsply Sirona (NASDAQ:XRAY) and its peers.

122. ▢Jun 16, 8:00 PMjournal

     options_momentum opened long 1,300 @ $0.32

123. ▣Jun 16, 8:00 PMjournalstop

     options_momentum closed long 1,300 @ $0.23 (-$116.89)

     Stop: premium $0.23 ≤ trailing floor $0.24 (peak $0.32 × 0.75)

124. ❖Jun 16, 1:53 PMnewsvia finnhub

     3 Small-Cap Stocks We Think Twice About

     Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

125. ❖Jun 15, 12:18 AMnewsvia finnhub

     How DENTSPLY SIRONA’s New Veteran CFO Could Shape Capital Allocation and Strategy for XRAY Investors

     DENTSPLY SIRONA has appointed John C. Fortson as Executive Vice President and Chief Financial Officer, effective July 20, 2026, bringing decades of experience in executive finance roles across industrial and materials companies and a background in investment banking and military service. This hire introduces a finance leader with prior CEO and CFO experience in complex, global manufacturing businesses, which may influence how DENTSPLY SIRONA approaches capital allocation, operational...

126. ▣Jun 10, 8:00 PMjournalstop

     options_momentum closed long 800 @ $0.40 (-$138.36)

     Stop: premium $0.40 ≤ trailing floor $0.43 (peak $0.57 × 0.75)

127. ▣Jun 9, 8:00 PMjournalstop

     options_momentum closed long 600 @ $0.56 (-$122.23)

     Stop: premium $0.56 ≤ trailing floor $0.57 (peak $0.76 × 0.75)

128. ▢Jun 9, 8:00 PMjournal

     options_momentum opened long 800 @ $0.57

129. ❖Jun 9, 6:54 AMnewsvia finnhub

     3 Unprofitable Stocks That Fall Short

     Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

130. ▢Jun 8, 8:00 PMjournal

     options_momentum opened long 600 @ $0.76

131. ▣May 25, 8:00 PMjournalmanual

     options_momentum closed long 4,200 @ $0.26 (+$52.27)

     Stop: premium $0.23 ≤ trailing floor $0.38 (peak $0.51 × 0.75)

132. ❖May 17, 5:40 AMnewsvia finnhub

     Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know

     A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with service-sector prices rising at their fastest pace in four years.

133. ▢May 13, 8:00 PMjournal

     options_momentum opened long 4,200 @ $0.25